Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Appointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. “We welcome Sanjeev to Phathom's leadership team at this important stage of our growth,” said Steve Basta, President and Chief Executive Officer of Phathom. “His extensive financial and operational expertise will be critical as we execute our strategy to achieve profitability and drive long-term shareholder value.” Mr. Narula commented, “This is an exciting moment to join Phathom, with VOQUEZNA gaining traction and a clear path for continued growth. I look forward to working with the talented team to drive financial performance and help unlock the company's full potential.
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]Seeking Alpha
- Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]Yahoo! Finance
- Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)GlobeNewswire
- Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.MarketBeat
PHAT
Earnings
- 10/30/25 - Beat
PHAT
Sec Filings
- 12/2/25 - Form 4
- 11/5/25 - Form 4
- 11/4/25 - Form SCHEDULE
- PHAT's page on the SEC website